[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"West Kazakhstan Marat Ospanov Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":150},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,58,79,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100647342","phase-1-safety-of-topical-exosome-containing-liquid-in-healthy-volunteers-for-future-surgical-wound-use-100647342",false,"NCT07707986","Safety of Topical Exosome-Containing Liquid in Healthy Volunteers for Future Surgical Wound Use","A Phase 1 Split-Site Pilot Study to Evaluate the Safety and Dermal Tolerability of Topical Exosome-Containing Liquid in Healthy Adult Volunteers Before Future Testing in Post-Melanoma-Excision Surgical Wounds","EV-MELSAFE","Inclusion Criteria:\n\n1. Healthy adult volunteers aged 18 to 55 years.\n2. Able and willing to provide written informed consent.\n3. No clinically significant abnormality based on medical history, physical examination, vital signs, and screening laboratory tests.\n4. Intact healthy skin at the planned application sites.\n5. Willingness to avoid applying other topical products, cosmetics, antiseptics, or irritant substances to the application sites during the study period.\n6. Willingness to avoid excessive sun exposure, sauna, swimming pool use, and mechanical irritation of the application sites during the study period.\n7. Willingness to comply with all study visits, topical application procedures, local skin assessments, skin photography, safety assessments, and follow-up.\n8. For women of childbearing potential, a negative pregnancy test before first application and willingness to use an acceptable method of contraception during the study period.\n\nExclusion Criteria:\n\n1. Any active skin disease, dermatitis, eczema, psoriasis, urticaria, acneiform eruption, skin infection, open wound, scar, tattoo, burn scar, pigmentation disorder, or clinically significant skin abnormality at the planned application sites.\n2. History of severe allergy, anaphylaxis, or hypersensitivity to topical liquids, dressings, biological products, exosome-containing products, or any component of the investigational product or vehicle liquid.\n3. Current acute illness, fever, or active infection.\n4. Known autoimmune disease, immunodeficiency, or current systemic immunosuppressive therapy.\n5. Use of systemic corticosteroids, immunomodulatory drugs, biological agents, or investigational products within 30 days before enrollment.\n6. Use of topical corticosteroids, topical immunomodulators, topical antibiotics, retinoids, keratolytic agents, or other medicated topical products on or near the planned application sites within 14 days before enrollment.\n7. Clinically significant hepatic, renal, cardiovascular, hematologic, endocrine, neurologic, psychiatric, or systemic disease that may increase risk or interfere with interpretation of study results.\n8. Known active malignancy or history of malignancy within the past 5 years.\n9. Positive screening test for clinically relevant transmissible infection, if required by the protocol.\n10. Pregnancy or breastfeeding.\n11. Positive pregnancy test at screening or before first application in women of childbearing potential.\n12. Participation in another interventional clinical trial within 30 days before enrollment.\n13. Blood donation or major blood loss within 30 days before enrollment, if laboratory safety monitoring is included in the protocol.\n14. Any condition that, in the investigator's judgment, would make participation unsafe or interfere with interpretation of study results.",true,"ALL","18 Years","55 Years",{"count":22,"type":23},10,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","This Phase 1 split-site pilot study will evaluate the safety and dermal tolerability of a topical exosome-containing liquid in 10 healthy adult volunteers. The investigational liquid will be applied to a small defined area of intact skin. A vehicle liquid without exosomes may be applied to a matched contralateral skin site as a control. The study will assess local skin reactions, systemic adverse events, vital signs, clinical laboratory parameters, and feasibility of topical administration. No melanoma lesion, surgical wound, burn wound, or artificial skin wound will be induced in participants in this Phase 1 safety study.",[29,30],"Healthy Volunteers (HV)","Skin Irritation",[32,33,34,35,36,37,38,39,40,41,42,43,44],"exosomes","extracellular vesicles","topical exosome-containing liquid","healthy volunteers","skin tolerability","skin irritation","phase 1","first-in-human","post-melanoma-excision wound","surgical wound repair","postoperative wound healing","Dermal Tolerability","dermal safety","NOT_YET_RECRUITING","2026-07-12",{"date":48,"type":49},"2026-07-16","ACTUAL",{"date":51,"type":23},"2026-09",{"date":53,"type":23},"2027-01",{"name":55,"class":56},"West Kazakhstan Marat Ospanov Medical University","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":65,"targetDuration":4,"studyType":24,"phases":66,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":78,"locationsCount":57},"100647093","phase-1-safety-of-topical-exosome-containing-liquid-in-healthy-volunteers-100647093","NCT07703969","Safety of Topical Exosome-Containing Liquid in Healthy Volunteers","A Phase 1 Split-Site Pilot Study to Evaluate the Safety and Dermal Tolerability of Topical Exosome-Containing Liquid in Healthy Adult Volunteers","EV-SAFE-1",{"count":22,"type":23},[26],"This Phase 1 split-site pilot study will evaluate the safety and dermal tolerability of a topical exosome-containing liquid in 10 healthy adult volunteers. The investigational liquid will be applied to a small defined area of intact skin. A vehicle liquid without exosomes may be applied to a matched contralateral skin site as a control. The study will assess local skin reactions, systemic adverse events, vital signs, clinical laboratory parameters, and feasibility of topical administration. No burn wound or artificial skin wound will be induced in participants in this Phase 1 safety study.",[30,69],"Healthy Volunteers",[32,33,34,35,44,36,37,38,39,71,72,73],"burn wound development","mesenchymal stromal cell-derived extracellular vesicles","dermal tolerability",{"date":75,"type":49},"2026-07-15",{"date":51,"type":23},{"date":53,"type":23},{"name":55,"class":56},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":57},"100632380","assessment-of-pancreatic-dysfunction-in-patients-with-type-2-diabetes-100632380","NCT07512934","Assessment of Pancreatic Dysfunction in Patients With Type 2 Diabetes","Integrated Assessment of Pancreatic Dysfunction in Patients With Type 2 Diabetes: a Cross-sectional Study Protocol","T3cDM-AKT","Inclusion Criteria:\n\n* • adult patients of Kazakh nationality aged 18 to 74 years\n* diagnosis of T2DM established according to ADA criteria and documented in medical records\n* disease duration ≤5 years\n* absence of ketoacidosis episodes within the last 6 months\n\nExclusion Criteria:\n\n* positive anti-glutamic acid decarboxylase antibodies (anti-GAD65);\n* acute or chronic infections affecting metabolic status within the previous 4 weeks;\n* any history of malignant neoplasms;\n* pregnancy or lactation;\n* previously diagnosed type 1 diabetes mellitus or other specific types of diabetes;\n* severe decompensated chronic diseases;\n* conditions associated with systemic fibrosis (e.g., liver cirrhosis or autoimmune diseases);\n* refusal to participate.","74 Years",{"count":89,"type":23},310,"OBSERVATIONAL","The goal of this observational study is to better understand how the pancreas works in adults with type 2 diabetes. The study focuses on both hormone production (endocrine function) and digestive function (exocrine function) of the pancreas.\n\nThe main questions it aims to answer are:\n\n* Can problems with the pancreas help identify a different type of diabetes called pancreatogenic diabetes?\n* How are blood markers and pancreas structure related to pancreatic function?\n\nParticipants will:\n\n* Have blood tests to measure glucose, insulin, and other markers\n* Provide a stool sample to assess digestive function\n* Undergo an ultrasound examination of the pancreas\n* Answer questions about digestive symptoms\n\nThe study will take place during a single visit in outpatient clinics.",[93,94,95],"Pancreatogenic Diabetes Mellitus","Type 2 Diabetes Mellitus (T2DM)","Exocrine Pancreatic Insufficiency (EPI)",[97,98,99,100,101,102,103,104,105],"Type 3c diabetes","Pancreatogenic diabetes","Fecal elastase-1","TGF-beta1","Adiponectin","IL-1 receptor antagonist","Pancreatic ultrasound","PEI-Q","Type 2 Diabetes Mellitus","RECRUITING","2026-04-02",{"date":109,"type":49},"2026-04-06",{"date":111,"type":49},"2025-07-07",{"date":113,"type":23},"2026-12-01",{"name":55,"class":56},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":24,"phases":126,"briefSummary":128,"conditions":129,"keywords":133,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":57},"100623213","metaphylaxis-of-infected-kidney-stones-after-percutaneous-nephrolithotripsy-100623213","NCT07393711","Metaphylaxis of Infected Kidney Stones After Percutaneous Nephrolithotripsy","Evaluation of the Effectiveness of Intrarenal Dioxidine Metaphylaxis for Preventing Recurrence of Infection Stones After Percutaneous Nephrolithotripsy","DIOX-PCNL","Inclusion Criteria:\n\nAge ≥18 years\n\nPatients undergoing percutaneous nephrolithotripsy (PCNL)\n\nInfection-related kidney stones\n\nAbility to provide written informed consent\n\nExclusion Criteria:\n\nAge \\\u003C18 years\n\nPregnancy or breastfeeding\n\nKnown hypersensitivity to dioxidine\n\nSevere renal insufficiency or end-stage renal disease\n\nSevere comorbid conditions that preclude participation","70 Years",{"count":125,"type":23},95,[127],"NA","Kidney stone recurrence, particularly infection-related stones, remains a significant clinical problem after percutaneous nephrolithotripsy (PCNL). Bacterial colonization and persistent infection are recognized contributors to stone recurrence.\n\nThis study evaluates the effectiveness of intrarenal dioxidine instillation as a metaphylactic measure to reduce recurrence of infection-related kidney stones following PCNL. Patients undergoing PCNL will receive standard treatment, with or without adjunctive intrarenal dioxidine administration. The study aims to assess whether this approach reduces stone recurrence and infection-related complications.",[130,131,132],"Kidney Calculi","Nephrolithiasis","Urinary Tract Infections",[134,135,136,137,138,139,140,141],"Percutaneous nephrolithotomy","PCNL","Infection stones","Struvite stones","Dioxidine","Intrarenal instillation","Stone recurrence","Metaphylaxis","2026-02-08",{"date":144,"type":49},"2026-02-11",{"date":146,"type":23},"2026-03-01",{"date":148,"type":23},"2026-12-30",{"name":55,"class":56},""]